A Phase 4 interventional study of Teriparatide and Alendronate in Osteoporosis, sponsored by Eli Lilly and Company. Completed at 20 sites in 4 countries. Open to female participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-04-14.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies testing teriparatide in Osteoporosis — 3 open to participants now, 5 under way, none of them phase 3. Teriparatide · Osteoporosis.
Among the 62 studies testing teriparatide in Osteoporosis, this one is the 8th largest by enrollment, is the only one that started in 2001, is one of 17 in phase 4, and was the 50th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →3 of the 62 studies testing teriparatide in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 45+ · Women only · Healthy volunteers
Peking Union Medical College Hospital · Sites in China
Ages 45–90
Paul F Netzel · Sites in United States
Ages 45+ · Women only
By country, each count listing its studies:
Teriparatide: first FDA approval 2002 (FORTEO), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 45 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 13 · Phase 4 17
First in 1987; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 203 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 63 across the 62 interventional studies. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 62 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 542 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
23 studies in Osteoporosis by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 23 finished, 14 (61%) have results posted.
Among the 23 studies in Osteoporosis by Eli Lilly and Company, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2001, is one of 8 in phase 4, and was the 23rd registered.
Eli Lilly and Company’s Osteoporosis studies by the year they started, since 2001.
2 of the studies testing teriparatide in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
| NCT06558188Massachusetts General HospitalCombined Anabolic Therapy | 2027-11-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies testing teriparatide in Osteoporosis, from their registry updates:
Among Eli Lilly and Company’s 23 in Osteoporosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
Drug: Teriparatide · Dietary Supplement: Calcium · Dietary Supplement: Vitamin D · Drug: Placebo-Oral
10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
Drug: Alendronate · Dietary Supplement: Calcium · Dietary Supplement: Vitamin D · Drug: Placebo-SC
Administered SC
Also known as: LY333334, Forteo, Forsteo
Administered orally
Administered orally
Administered orally
Administered orally
Administered SC
Percent Change from Baseline to 18 Months in Lumbar Spine BMD
Time frame: Baseline, 18 Months
Percent Change from Baseline in Lumbar Spine BMD
Time frame: Baseline, 3 Months, 6 Months, 12 Months
Percent Change from Baseline in Total Hip and Femoral Neck BMD
Time frame: Baseline, 12 Months, 18 Months
Percent Change from Baseline in Trabecular Volumetric BMD at the Lumbar Spine
Time frame: Baseline, 6 Months, 18 Months
Percent Change from Baseline in Cortical BMD at the Femoral Neck
Time frame: Baseline, 6 Months, 18 Months
Percent Change from Baseline in Trabecular BMD at the Femoral Neck
Time frame: Baseline, 6 Months, 18 Months
Percent Change from Baseline in Biochemical Marker -Serum Procollagen I C-Terminal Propeptide (PICP)
Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months
Percent Change from Baseline in Biochemical Marker -Serum Procollagen I N-Terminal Propeptide (PINP)
Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months
Percent Change from Baseline in Biochemical Marker -Bone-Specific Alkaline Phosphatase (BSAP)
Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months
Percent Change from Baseline in Biochemical Marker -Urinary N-Telopeptide (NTX)
Time frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months
Percentage of Participants with Nonvertebral Fractures
Time frame: 18 Months
Percentage of Participants with Clinical Fractures
Time frame: 18 Months
Change from Baseline on the Back Pain Questionnaire
Time frame: Baseline, 3 Months, 6 Months, 18 Months
The record gives a start of Apr 2001, a primary completion of May 2003 and a completion of May 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teriparatide